verona pharma merck - Search News

News

Merck shells out $10 billion for Verona

Reuters on MSN · 2d

Merck shells out $10 billion for Verona in bid to diversify beyond Keytruda

Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory treatment as it faces pressure to diversify beyond its blockbuster cancer drug Keytruda.

The Wall Street Journal on MSN · 1d

Merck to Buy Verona Pharma in $10 Billion Deal

The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.

MarketWatch on MSN · 2d

Merck dives into COPD treatments with $10 billion purchase of Verona Pharma

Merck & Co. is acquiring Verona Pharma PLC in a $10 billion deal that will expand the pharmaceutical giant’s portfolio of chronic obstructive pulmonary disease treatments with Verona Pharma’s Ohtuvayre.

10h

Merck's Verona Acquisition: Plugging A $4B Hole In A $20B Gap

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

BioPharma Dive6h

With Verona deal, Merck wagers on strength of lung drug’s patents

The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...

1don MSN

Merck Acquires Verona Pharma for $10B to Support Portfolio with COPD Drug Ohtuvayre Ahead of Keytruda Patent Expiration

Merck & Co. Inc. (NYSE:MRK) is one of the most undervalued NYSE stocks to buy now. On July 9, Merck announced its acquisition ...

2don MSN

Merck nears about $10 billion deal for London-based lung therapy firm Verona, FT reports

U.S. drugmaker Merck is nearing a deal worth about $10 billion to buy Verona Pharma, a company focused on therapies for lung ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results